These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 12353814)

  • 1. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
    Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
    Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
    Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
    Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models.
    Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
    Cancer Treat Rev; 1999 Oct; 25(5):293-9. PubMed ID: 10544073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.
    Neudert M; Fischer C; Krempien B; Bauss F; Seibel MJ
    Int J Cancer; 2003 Nov; 107(3):468-77. PubMed ID: 14506749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
    Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
    Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
    Body JJ; Diel IJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Ann Oncol; 2003 Sep; 14(9):1399-405. PubMed ID: 12954579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment.
    Richert MM; Phadke PA; Matters G; DiGirolamo DJ; Washington S; Demers LM; Bond JS; Manni A; Welch DR
    Breast Cancer Res; 2005; 7(5):R819-27. PubMed ID: 16168128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
    Magnetto S; Boissier S; Delmas PD; Clezardin P
    Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
    Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
    Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R
    J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
    Li JJ; Chen WL; Wang JY; Hu QW; Sun ZP; Zhang S; Liu S; Han XH
    Acta Pharmacol Sin; 2017 Oct; 38(10):1369-1380. PubMed ID: 28414206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
    Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases.
    El-Mabhouh AA; Nation PN; Abele JT; Riauka T; Postema E; McEwan AJ; Mercer JR
    Oncol Res; 2011; 19(6):287-95. PubMed ID: 21776824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mono- and Combined Therapy of Metastasizing Breast Carcinoma 4T1 with Zoledronic Acid and Doxorubicin.
    Baklaushev VP; Grinenko NF; Yusubalieva GM; Gubskii IL; Burenkov MS; Rabinovich EZ; Ivanova NV; Chekhonin VP
    Bull Exp Biol Med; 2016 Aug; 161(4):580-6. PubMed ID: 27590765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.